Replies to post #219541 on Biotech Values

[DewDiligence]

ONCE -32% on safety issue—neutralizing antibodies—in phase-1/2 trial:

https://finance.yahoo.com/m/066127de-704f-3669-b492-5ffc62723a34/spark-therapeutics-stock.html

https://finance.yahoo.com/news/spark-therapeutics-reports-second-quarter-113000041.html